ArticleCureus2025
A Case Report of Neuromyelitis Optica Spectrum Disorder in a Young Patient With Systemic Lupus Erythematosus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinally extensive transverse myelitis as a manifestation of neuro-chikungunya in a lupus patient: a case report.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica spectrum disorder (NMOSD), previously neuromyelitis optica, is an autoimmune, inflammatory CNS syndrome that can present in a variety of manifestations. It is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG); however, its presence is not required for the diagnosis. In this report, a rare case of NMOSD is presented in a patient with systemic lupus erythematosus (SLE). The patient is a 21-year-old female with SLE who presented with intractable nausea, vomiting and hiccups. She underwent a thorough gastrointestinal workup that was non-revealing. A CNS workup was initiated ultimately revealing the diagnosis of NMOSD. Her symptoms resolved after initiating high-dose intravenous steroids and she was subsequently started on rituximab. In patients presenting with area postrema syndrome, in the setting of an established autoimmune disorder, clinicians should have a high clinical suspicion of NMOSD. An MRI of the brain and checking for serum AQP-4 IgG are important in making the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.